Kazia Therapeutics Intends To Request And Hold Follow-Up Type C Meeting With FDA To Discuss OS Findings In Newly Diagnosed Glioblastoma Patients Treated With Paxalisib

Kazia Therapeutics Limited ("Kazia" or the "Company") today announced its intention to request and hold a follow-up Type C meeting with the U.S. Food & Drug Administration (FDA) to discuss overall survival (OS) findings in newly diagnosed glioblastoma (GBM) patients treated with paxalisib and to seek agency feedback on a potential regulatory pathway aligned with the FDA Oncology Center of Excellence's Project FrontRunner initiative.